Abbott Laboratories $ABT Shares Bought by IFP Advisors Inc

IFP Advisors Inc raised its stake in Abbott Laboratories (NYSE:ABT) by 176.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,041 shares of the healthcare product maker’s stock after acquiring an additional 35,785 shares during the period. IFP Advisors Inc’s holdings in Abbott Laboratories were worth $7,021,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Freemont Management S.A. boosted its position in shares of Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $116,580,000. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories during the third quarter worth approximately $185,640,000. Thrivent Financial for Lutherans boosted its position in shares of Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after buying an additional 48,286 shares during the period. Finally, AE Wealth Management LLC boosted its position in shares of Abbott Laboratories by 20.8% during the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after buying an additional 11,264 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on ABT. Leerink Partners dropped their target price on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. JPMorgan Chase & Co. dropped their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Citigroup dropped their target price on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. TD Cowen dropped their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Oppenheimer dropped their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $119.43.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock worth $353,097 over the last 90 days. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $88.38 on Thursday. The company’s fifty day moving average is $97.65 and its two-hundred day moving average is $112.47. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a market cap of $153.93 billion, a P/E ratio of 24.76, a price-to-earnings-growth ratio of 1.48 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the business earned $1.09 EPS. The company’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.